Stock Research for CNAT

CNAT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CNAT Stock Chart & Research Data

The CNAT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNAT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CNAT Due diligence Resources & Stock Charts

The CNAT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CNAT Detailed Price Forecast - CNN Money CNN View CNAT Detailed Summary - Google Finance
Yahoo View CNAT Detailed Summary - Yahoo! Finance Zacks View CNAT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CNAT Trends & Analysis - Trade-Ideas Barrons View CNAT Major Holders - Barrons
NASDAQ View CNAT Call Transcripts - NASDAQ Seeking View CNAT Breaking News & Analysis - Seeking Alpha
Spotlight View CNAT Annual Report - CompanySpotlight.com OTC Report View CNAT OTC Short Report - OTCShortReport.com
TradeKing View CNAT Fundamentals - TradeKing Charts View CNAT SEC Filings - Bar Chart
WSJ View Historical Prices for CNAT - The WSJ Morningstar View Performance/Total Return for CNAT - Morningstar
MarketWatch View the Analyst Estimates for CNAT - MarketWatch CNBC View the Earnings History for CNAT - CNBC
StockMarketWatch View the CNAT Earnings - StockMarketWatch MacroAxis View CNAT Buy or Sell Recommendations - MacroAxis
Bullish View the CNAT Bullish Patterns - American Bulls Short Pains View CNAT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CNAT Stock Mentions - StockTwits PennyStocks View CNAT Stock Mentions - PennyStockTweets
Twitter View CNAT Stock Mentions - Twitter Invest Hub View CNAT Investment Forum News - Investor Hub
Yahoo View CNAT Stock Mentions - Yahoo! Message Board Seeking Alpha View CNAT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CNAT - SECform4.com Insider Cow View Insider Transactions for CNAT - Insider Cow
CNBC View CNAT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CNAT - OTC Markets
Yahoo View Insider Transactions for CNAT - Yahoo! Finance NASDAQ View Institutional Holdings for CNAT - NASDAQ


Stock Charts

FinViz View CNAT Stock Insight & Charts - FinViz.com StockCharts View CNAT Investment Charts - StockCharts.com
BarChart View CNAT Stock Overview & Charts - BarChart Trading View View CNAT User Generated Charts - Trading View




Latest Financial News for CNAT


Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
Posted on Wednesday December 12, 2018

A low key week for the biotech sector with focus on regular pipeline updates.


The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
Posted on Friday December 07, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...


Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
Posted on Thursday December 06, 2018

Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.


Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
Posted on Thursday December 06, 2018

Shares of Conatus Pharmaceuticals Inc. plummeted 53% Thursday after the company announced its Phase 2 clinical trial of emricasan did not meet its primary endpoint. Patients with liver damage from nonalcoholic fatty liver disease did not show sufficient patient improvement on the drug compared to a placebo. Stifel analysts downgraded the company to hold from buy and lowered their price target to $4 from $10, while analysts at SunTrust Robinson Humphrey lowered their price target to $12 from $20. Friday's selloff puts the biotech's stock on track to suffer its biggest one-day percentage decline since the company went public in July 2013. Shares of Conatus have fallen 53% in the year to date, and the S&P 500 has fallen 0.1%.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.